Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 63

1.

Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.

Mills EJ, Rachlis B, O'Regan C, Thabane L, Perri D.

BMC Cancer. 2009 Jan 27;9:34. doi: 10.1186/1471-2407-9-34. Review.

PMID:
19173737
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.

Thompson Coon J, Hoyle M, Green C, Liu Z, Welch K, Moxham T, Stein K.

Health Technol Assess. 2010 Jan;14(2):1-184, iii-iv. doi: 10.3310/hta14020. Review.

PMID:
20028613
[PubMed - indexed for MEDLINE]
Free Article
3.

Targeted therapy for metastatic renal cell carcinoma.

Motzer RJ, Bukowski RM.

J Clin Oncol. 2006 Dec 10;24(35):5601-8. Review.

PMID:
17158546
[PubMed - indexed for MEDLINE]
Free Article
4.

Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.

Hutson TE.

Oncologist. 2011;16 Suppl 2:14-22. doi: 10.1634/theoncologist.2011-S2-14. Review.

PMID:
21346036
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.

Thompson Coon JS, Liu Z, Hoyle M, Rogers G, Green C, Moxham T, Welch K, Stein K.

Br J Cancer. 2009 Jul 21;101(2):238-43. doi: 10.1038/sj.bjc.6605167. Epub 2009 Jun 30. Review.

PMID:
19568242
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.

Chowdhury S, Larkin JM, Gore ME.

Eur J Cancer. 2008 Oct;44(15):2152-61. doi: 10.1016/j.ejca.2008.06.028. Epub 2008 Sep 29. Review.

PMID:
18829302
[PubMed - indexed for MEDLINE]
7.

[Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].

de Mulder PH, Haanen JB, Sleijfer S, Kruit WH, Gietema JA, Richel DJ, Groenewegen G, Voest EE, van den Eertwegh AJ, Osanto S, Jansen RL, Mulders PF.

Ned Tijdschr Geneeskd. 2008 Feb 16;152(7):371-5. Review. Dutch.

PMID:
18380383
[PubMed - indexed for MEDLINE]
8.

Targeted treatment for metastatic renal cell carcinoma and immune regulation.

Laschos KA, Papazisis KT, Kontovinis LF, Kalaitzis C, Gianakopoulos S, Kortsaris AH, Touloupidis S.

J BUON. 2010 Apr-Jun;15(2):235-40. Review.

PMID:
20658715
[PubMed - indexed for MEDLINE]
9.

[Effect of angiogenesis inhibitors on renal cell carcinoma].

Bodrogi I.

Magy Onkol. 2007;51(2):145-53. Epub 2007 Jul 29. Review. Hungarian.

PMID:
17660871
[PubMed - indexed for MEDLINE]
Free Article
10.

[Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].

Barrascout E, Medioni J, Scotte F, Ayllon J, Mejean A, Cuenod CA, Tartour E, Elaidi R, Oudard S.

Bull Cancer. 2010;97:29-43. doi: 10.1684/bdc.2010.1068. Review. French.

PMID:
20418202
[PubMed - indexed for MEDLINE]
11.

[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].

Miller K, Bergmann L, Jäger E, Jakse G, Wirth M, Keilholz U; interdisziplinäre Arbeitsgruppe Nierenzellkarzinom der Deutschen Krebsgesellschaft e.V. (DKG).

Aktuelle Urol. 2009 Jan;40(1):27-30. doi: 10.1055/s-0028-1098786. Epub 2009 Jan 28. German.

PMID:
19177318
[PubMed - indexed for MEDLINE]
12.

Systemic therapy for metastatic renal cell carcinoma.

Kroog GS, Motzer RJ.

Urol Clin North Am. 2008 Nov;35(4):687-701; ix. doi: 10.1016/j.ucl.2008.07.007. Review.

PMID:
18992622
[PubMed - indexed for MEDLINE]
13.

Tolerability of first-line therapy for metastatic renal cell carcinoma.

Porta C, Szczylik C.

Cancer Treat Rev. 2009 May;35(3):297-307. doi: 10.1016/j.ctrv.2008.12.003. Epub 2009 Feb 26. Review.

PMID:
19249157
[PubMed - indexed for MEDLINE]
14.

New therapeutic approaches in the management of metastatic renal cell carcinoma.

Gkialas IK, Papadopoulos G.

J BUON. 2009 Jul-Sep;14(3):399-404. Review.

PMID:
19810129
[PubMed - indexed for MEDLINE]
15.

Treatment options for metastatic renal cell carcinoma: a review.

Athar U, Gentile TC.

Can J Urol. 2008 Apr;15(2):3954-66. Review.

PMID:
18405442
[PubMed - indexed for MEDLINE]
16.

Progress in the management of advanced renal cell carcinoma (RCC).

Tong TQ, Rohde D, Peter S.

Aktuelle Urol. 2010 Jan;41 Suppl 1:S57-60. doi: 10.1055/s-0030-1247237. Epub 2010 Jan 21. Review.

PMID:
20094957
[PubMed - indexed for MEDLINE]
17.

Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.

Pouessel D, Culine S.

Expert Rev Anticancer Ther. 2006 Dec;6(12):1761-7. Review.

PMID:
17181490
[PubMed - indexed for MEDLINE]
18.

[First-line therapy of metastatic renal cell carcinoma--update 2009].

Miller K.

Onkologie. 2010;33 Suppl 1:5-9. doi: 10.1159/000265688. Epub 2010 Jan 22. Review. German.

PMID:
20164669
[PubMed - indexed for MEDLINE]
19.

Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations.

Norum J, Nieder C, Kondo M.

J Chemother. 2010 Apr;22(2):75-82. Review.

PMID:
20435564
[PubMed - indexed for MEDLINE]
20.

New therapies in renal cell carcinoma.

Patard JJ, Pouessel D, Culine S.

Curr Opin Support Palliat Care. 2007 Oct;1(3):174-9. doi: 10.1097/SPC.0b013e3282f1238b. Review.

PMID:
18685359
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk